Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion type Assertion NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_head.
- NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion description "[The development of therapeutic approaches that inhibit PCSK9 function has therefore attracted considerable attention from clinicians and the pharmaceutical industry for the management of hypercholesterolemia and its associated cardiovascular disease risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_provenance.
- NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion evidence source_evidence_literature NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_provenance.
- NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion SIO_000772 26503748 NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_provenance.
- NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion wasDerivedFrom befree-2016 NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_provenance.
- NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_assertion wasGeneratedBy ECO_0000203 NP1295227.RA7K3-F8ipvQKMdJFMT_Ol5huMiHvTpj5i3xsm0xqAcm8130_provenance.